Ann: International institution acquires 14% of Neuren, page-49

certainly Walker's operation was agreed to three, for timing, dynamics and numbers. it is clear that Neuren knew to whom he would transfer his Walker shares and at what price. everything suggests that there is a strategic plan in place, resulting from Neuren's refusal of an offer accrued over many months with Torreya's advice.Strong suspicions are also intrinsic to Acadia / Neuren's decision to suspend enrollment, when the remaining Acadia trials remain active and unconditionally. we know for certain that, in principle, that the FDA request was to replicate the results obtained in phase 2 by Neuren. a more ambitious and higher dose study was planned without prejudice to the absence of toxicity. that said, it is not the first time that I have read conditional concessions from the FDA, particularly in unsatisfied and rare diseases, for an authorization to make the drug available to all subjects with pathology, while continuing the trial in its various stages. in this specific case, the rect trial was designed in two levels, of which the first has already acquired important elements of evaluation. this to add a further element of reflection that could justify the stop of enrollments for the second phase of the study. all hypotheses that could advance behind the delay.